This register-based cohort study from Denmark of 503,158 clinically recognized pregnancies observed little or no risk of teratogenesis associated with first trimester exposure to antipsychotic medications.
In this multicenter cohort, maternal cannabis use documented using urine drug sampling was associated with increased risk of adverse pregnancy outcomes related to placental dysfunction.
Lithium use during pregnancy was associated with an increased risk of preterm birth and large for gestational age infants.
There is evidence that depression itself can increase risk for hypertension and preeclampsia. Future studies will help to clarify the complex interaction between depression, SSRI treatment and pre-eclampsia.
Diagnosis of a mood or anxiety disorder during pregnancy was associated with a 3.5-fold increase in adverse perinatal outcomes.
In this retrospective study of Taiwanese women using antipsychotic medications there was no observed increase in risk of metabolic complications.
Largest studies to date demonstrate statistically significant risk of preterm birth among women with active PTSD.
All of our information on the reproductive safety of medications comes from non-randomized studies. However, many of these studies fail to take into consideration other factors associated with maternal psychiatric illness which may also affect outcomes.
Prenatal cannabis exposure was associated with persisting vulnerability to psychopathology throughout early adolescence.
Prenatal opioid use is associated with increased maternal and infant mortality, prematurity, and poor neonatal outcomes.
